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OBJECTIVES: To compare imprint cytology and paraffin section histology for sentinel lymph node detection in
women with breast cancer treated with neoadjuvant chemotherapy.
METHOD: A cross-sectional study and report of the sentinel lymph node statuses of 64 patients with breast
cancer who underwent intraoperative imprint cytology and neoadjuvant chemotherapy in a referral cancer
institute in Rio de Janeiro, Brazil, between 2014 and 2016.
RESULTS: The mean age was 51 years. The most common histological type was invasive ductal carcinoma
(93.75%), and the most common differentiation grade was 2 (62.5%). Overall, 153 lymph nodes were identified,
with a mean of 2.39/case. Thirty-four lymph nodes tested positive for malignancy by imprint cytology, and
55 tested positive by histology. Of the 55 positive lymph nodes, 41 (74.5%) involved macrometastases, and
14 (25.5%) involved micrometastases. There were 21 false negatives with imprint cytology, namely, 7 for
macrometastases and 14 for micrometastases, resulting in a rate of 17.6%. The sensitivity of imprint cytology
was 61.8%, with a specificity and positive predictive value of 100%, a negative predictive value of 82.4% and an
accuracy of 86.3%. The method presented null sensitivity for the identification of micrometastases.
CONCLUSIONS: The false-negative rate with imprint cytology was associated with the number of sentinel lymph
nodes obtained. The rate found for complete response to neoadjuvant chemotherapy was comparable to the
rates reported in the literature. The accuracy of imprint cytology was good, and its specificity was excellent for
sentinel lymph node detection; however, the method was unable to detect lymph node micrometastases.
KEYWORDS: Imprint; Breast Cancer; Neoadjuvant Chemotherapy; Histology; Accuracy.
’ INTRODUCTION
Breast cancer is the most prevalent cancer type in Brazilian
women. According to the National Cancer Institute (INCA),
57,960 new cases are expected for the 2016-2017 period (1).
Axillary staging is a key step in the treatment of breast
cancer. For many years, axillary dissection was the standard
method used in most cases, being considered an important
factor in predicting recurrence and survival (2). In Brazil,
more extensive surgeries and axillary dissections are often
used, although these procedures are associated with the
occurrence of both short- and long-term complications, the
most common being hemorrhage, infection, seroma, upper
limb lymphedema, chronic pain, and paresthesia resulting
from injury to the intercostobrachial nerve (3,4).
Sentinel lymph node biopsy (SLNB) permits lymph node
staging and is considered the gold standard method for the
evaluation of axillary lymph node status for patients without
clinical suspicion of lymph node involvement. SLNB has
been used in clinical practice for over a decade and has
considerably reduced the morbidity associated with axillary
surgery and resulted in axillary lymph node dissection. Now,
SLNB is restricted to specific situations (5).
The most relevant studies, including the Axillary Lym-
phatic Mapping Against Nodal Axillary Clearance (ALMA-
NAC) trial, have recommended SLNB as a safe and effective
procedure, with the potential for less morbidity and better
quality of life than routine axillary dissection (6). The Natio-
nal Surgical Adjuvant Breast and Bowel Project (NSABP)
B-32 trial evaluated 3,986 cases that were divided into two
groups, with Group A comprising patients subjected to
SLNB followed by axillary lymphadenectomy and with
Group B comprising patients subjected to SLNB and sub-
sequent lymphadenectomy alone if the result of the former
was positive. No significant differences were found between
the two groups with respect to overall survival, disease-freeDOI: 10.6061/clinics/2018/e363
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survival or recurrence control. Approximately 85% of cases
in both groups underwent adjuvant therapy (7).
A debate has arisen regarding the sentinel lymph node
(SLN) identification rate, the false-negative rate, and the
accuracy and safety of SLNB when performed after neo-
adjuvant chemotherapy. Boughey et al. evaluated the SLN
identification rate after neoadjuvant chemotherapy in patients
enrolled in the American College of Surgical Oncology Group
(ACOSOG) Z1071 trial (8). In this study, SLNs were identified
in 78.6% of cases when patent blue dye alone was used, in
91.4% of cases when radiolabeled colloid alone was used,
and in 93.8% of cases when dual mapping agents were
used. A false-negative rate of 12.6% was found when fewer
than two SLNs were removed; however, this rate decreased
to 9.1% when more than two SLNs were available. Other
factors, namely, body mass index, the tumor stage and the
patient’s response to neoadjuvant chemotherapy, did not
affect SLN detection.
During surgery, pathological analysis is performed on
SLNs using techniques that include intraoperative frozen
sections, imprint cytology and immunohistochemistry. How-
ever, the gold standard method is paraffin section histology
following surgery (9).
Of the different methods used to evaluate SLNs, imprint
cytology is the most commonly used. The initial route of
breast cancer dissemination follows the axillary lymph nodes,
and metastatic involvement of the axilla generally progresses
from the first to the second and then third level of axillary
nodes. Metastases that fail to adhere to this sequence are rare,
making up 2% of cases, and are referred to as skip metastases.
Therefore, an intraoperative analysis of SLNs that is fast and
precise is of vital importance for minimizing the need for
repeat surgery in patients with sentinel lymph nodes affected
by metastases (10).
In recent years, the use of SLNB has been established as an
important tool in the treatment of patients with early stage
breast cancer, differentiating those who need radical axillary
lymphadenectomy from those who do not. The use of radical
axillary lymphadenectomy has declined following the intro-
duction of SLN analysis, with a consequent decrease in the
rate of associated complications. Nevertheless, the major con-
cern with SLNB is the occurrence of false negatives from the
intraoperative evaluation. False negativity may require a
patient to be subjected to an additional surgical procedure,
and the proportion of such cases ranges from 4.7 to 16.7%
following histological analysis of paraffin-embedded speci-
mens, thus resulting in therapeutic delay, with a significant
increase in treatment cost (11-13).
The objective of the present study was to compare imprint
cytology with paraffin section histology for the detection of
SLNs in women with breast cancer treated with neoadjuvant
chemotherapy.
’ MATERIALS AND METHODS
This cross-sectional, descriptive study was conducted
between 2014 and 2016 and included female patients of
any age with a diagnosis of breast cancer and a report of the
SLN status. All patients included in this study had under-
gone complete neoadjuvant chemotherapy at the National
Cancer Institute and had been examined by intraoperative
imprint cytology. Lymph nodes were identified during sur-
gery using dual mapping agents with radiolabeled colloid
and patent blue dye.
The following data were collected from the patients’ charts:
age; tumor diameter; the histological characteristics of the
tumor (type and grade of differentiation); SLN status based on
the intraoperative diagnosis and on the definitive histological
diagnosis; and the patient’s clinical and radiological response
to chemotherapy, classified as partial or complete. Pathologists
at the institute performed intraoperative analysis of the SLNs
using imprint cytology, with the slides being observed under
an optical microscope. Regardless of the imprint cytology
result, the remaining material was paraffin-embedded for
the definitive histological diagnosis, thus confirming the
positivity or negativity of the lymph node evaluated. Nodal
metastases were classified as micrometastases (p2 mm) or
macrometastases (42 mm) (14).
The sensitivity, specificity, accuracy, and positive and
negative predictive values were calculated according to the
standard formulae.
Ethics
This study was approved by the internal review board
of the Brazilian National Cancer Institute (INCA), Rio de
Janeiro, Brazil. The procedures were in accordance with the
ethical standards of the responsible committee and with the
Helsinki Declaration of 1975, as revised in 1983. The princi-
pal investigator alone collected all of the data, which were
immediately anonymized.
’ RESULTS
All medical charts available for the study period were
reviewed according to the inclusion criteria, resulting in
64 charts being selected. The mean age of the patients was
51 years (range 25-83 years). Thirty-two patients (50%) were
p50 years of age, and 44 women (68.8%) were menopausal.
The most common histological type was invasive ductal
carcinoma, making up 93.75% of cases, with the remaining
cases comprising invasive lobular carcinoma. The most com-
mon grade of differentiation was 2 (62.5%), followed by 3
(26.2%) and 1 (10.9%). Immunohistochemistry revealed that
14% of the cases were triple-negative, 15.6% were human
epidermal growth factor receptor 2 (HER2)-positive, and 73%
were estrogen receptor (ER)-positive. Regarding tumor size,
51.5% of the cases were classified as T2, namely, between 2
and 5 cm, 35.9% were classified as T3, and 12.5% were classi-
fied as T1. No lymph node involvement was present in 62.5%
of the cases; however, 32.8% were classified as N1, and 4.7%
were classified as N2 (Table 1).
A total of 153 lymph nodes were identified in the 64 cases,
with a mean of 2.39 lymph nodes per patient. A total of 34
lymph nodes tested positive for malignancy by intraopera-
tive imprint cytology. Later, definitive histological diagnoses
using paraffin-embedded surgical specimens revealed a total
of 55 positive lymph nodes (Table 2).
These 55 positive lymph nodes were subdivided into 41
positive cases involving macrometastases and 14 positive
cases involving micrometastases. Imprint cytology yielded
21 false negatives: 7 referring to macrometastases (Table 3) and
14 referring to micrometastases (Table 4). The false-negative
rate was 17.6% for imprint cytology.
In 24 cases, the clinical and radiological response to neo-
adjuvant chemotherapy was complete. In the cases with false
negatives for macrometastases, the response to chemother-
apy was partial, while in 4 cases (28.6%) with false negatives
2
Detection of sentinel lymph nodes
Delgado-Bocanegra RE et al.
CLINICS 2018;73:e363
for micrometastases, the response to chemotherapy was
complete.
Overall, when both macrometastases and micrometastases
were considered, imprint cytology had a sensitivity of 61.8%,
a specificity and positive predictive value of 100%, a negative
predictive value of 82.4%, and an accuracy of 86.3%. When
stratified into micrometastases and macrometastases, sensi-
tivity was null for micrometastases, so specificity was 100%
(Table 5).
’ DISCUSSION
Breast cancer management has undergone many changes
in recent years, particularly where treatment is concerned,
with the objective of improving the effectiveness and tole-
rance of treatment. Axillary status is an important prognostic
factor in breast cancer and may be a determinant indicating
whether systemic adjuvant therapy should be administered
(12). Axillary management in patients with breast cancer has
improved significantly over recent decades, with SLNB hav-
ing become the standard procedure for axillary staging in
patients without clinically detectable lymph nodes (cN0) (11).
The National Comprehensive Cancer Network (NCCN)
and ACOSOG have proposed that axillary lymphadenect-
omy be restricted to specific situations, based on the failure
of the ACOSOG Z0011 trial to find any differences in disease-
free survival or overall survival between the groups rando-
mized to axillary lymphadenectomy and SLNB alone groups
(15). Accordingly, axillary lymphadenectomy could be ruled
out for patients subjected to conservative surgery, those with
Table 1 - Baseline clinical characteristics of the study sample
(n=64).
n (%)
Age group (years)
o30 2 (3.2)
30–40 12 (18.7)
41–50 18 (28.1)
450 32 (50)
Histological type
Invasive ductal carcinoma 60 (93.75)
Invasive lobular carcinoma 4 (6.25)
Grade of differentiation
Grade 1 7 (10.9)
Grade 2 40 (62.5)
Grade 3 17 (26.6)
Tumor size
T1 (o2 cm) 8 (12.5)
T2 (2-5 cm) 33 (51.6)
T3 (45 cm) 23 (35.9)
Lymph node involvement
No involvement (N0) 40 (62.5)
N1 21 (32.8)
N2 3 (4.7)
Immunohistochemistry
Triple-negative 9 (14)
HER2-positive 10 (15.6)
HER2-negative 54 (84.4)
Estrogen receptor-positive 47 (73.43)
Estrogen receptor-negative 17 (26.57)
Progesterone receptor-positive 40 (62.5)
Progesterone receptor-negative 24 (37.5)
HER2: Human Epidermal Growth Factor Receptor 2.
Table 2 - Comparison of imprint cytology and histology for the detection of sentinel lymph node positivity for macrometastases and
micrometastases.
Positive by histology Negative by histology Total n (%)
Positive by imprint cytology 34 0 34 (22.2)
Negative by imprint cytology 21 98 119 (77.8)
Total n (%) 55 (35.9) 98 (64.1) 153 (100)
Table 3 - Comparison of imprint cytology and histology for the detection of sentinel lymph node positivity for macrometastases.
Positive by histology Negative by histology Totaln (%)
Positive by imprint cytology 34 0 34 (24.5)
Negative by imprint cytology 7 98 105 (75.5)
Total n (%) 41 (29.5) 98 (70.5) 139 (100)
Table 4 - Comparison of imprint cytology and histology for the detection of sentinel lymph node positivity for micrometastases.
Positive by histology Negative by histology Total n (%)
Positive by imprint cytology 0 0 0 (0)
Negative by imprint cytology 14 98 112 (100)
Total n (%) 14 (12.5) 98 (87.5) 112 (100)
Table 5 - Sensitivity, specificity, positive and negative predictive values, and accuracy of imprint cytology.
Imprint cytology Sensitivity Specificity Positive predictive value Negative predictive value Accuracy
Lymph node positivity for macrometastases
and micrometastases
61.8% 100% 100% 82.4% 86.3%
Lymph node positivity for macrometastases 82.9% 100% 100% 93.3% 95%
Lymph node positivity for micrometastases 0% 100% 0% 87.5% 87.5%
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T1-T2 tumors, those with p2 positive SLNs, those under-
going radiotherapy planning, and those not subjected
to neoadjuvant chemotherapy. These recommendations
have led to a reduction in the rate of axillary lymphade-
nectomies in breast cancer patients with positive SLNBs
worldwide (16).
Additionally, according to the NCCN, patients suitable
for neoadjuvant chemotherapy with no axillary involvement
detected by clinical palpation or ultrasound prior to initiat-
ing chemotherapy are candidates for SLNB following treat-
ment. If any suspicious ultrasound images exist, fine-needle
aspiration (FNA) biopsy should be performed. If no lymph
node involvement is detected, SLNB can be performed after
neoadjuvant chemotherapy. On the other hand, if the FNA
biopsy is positive prior to chemotherapy, axillary restag-
ing should be performed after chemotherapy, with axillary
lymphadenectomy being indicated if the axilla is clinically
affected or with SLNB if the axilla is clinically negative. For
these patients, intraoperative evaluations of SLNs should be
performed because if the lymph nodes are affected, axillary
lymphadenectomy is recommended (15).
Mansel et al. (6) reported data for a group of patients
with positive lymph nodes that were identified prior to
neoadjuvant chemotherapy. SLNB was shown to have a
false-negative rate above 10% after chemotherapy. In the
present study, imprint cytology had an overall rate of false-
negative lymph nodes (i.e., failing to identify both macro-
metastases and micrometastases) of 17.6% compared with
paraffin section histology.
Neoadjuvant chemotherapy is a widely accepted treat-
ment for breast cancer, and neoadjuvant chemotherapy and
adjuvant therapy are equally effective options. The princi-
pal advantages include the possibility of conducting an
in vivo evaluation of the sensitivity of the tumor to chemo-
therapy, the likelihood of reducing micrometastatic disease
and the consequent need for a less extensive form of sur-
gery with less morbidity (17).
Recently, the early detection rate, better known as down-
staging, has been approximately 94% in patients with breast
cancer. Furthermore, a pathological complete response has
been achieved in 20-40% of patients following neoadjuvant
chemotherapy. Evidently, a pathological complete response
is associated with a better prognosis and longer overall sur-
vival (18). Neoadjuvant chemotherapy can decrease the risk
of residual axillary disease and may be able to completely
eradicate axillary metastases detected by histology in patients
with locally advanced breast cancer (19).
The SENTINA study showed that lymph node disease was
restricted to the SLNs in 58% of patients who converted from
clinically node-positive to clinically node-negative breast
cancer following neoadjuvant chemotherapy, with the false-
negative rate decreasing significantly with the number of
SLNs removed. In patients who had one SLN removed, the
false-negative rate was 24.3% compared to 18.5% when two
SLNs were removed and less than 10% when three SLNs
were removed. Another important finding was that the false-
negative rate was 8.6% in patients subjected to dual mapping
agents (radiolabeled colloid and patent blue) for the detec-
tion of SLNs (20). In the present study, dual mapping agents
had been used in all selected cases, and the mean number
of SLNs obtained per case was 2.39. Since there was no
axillary dissection in the cases that tested negative accord-
ing to imprint cytology and histology, calculating the false-
negative rate of SLNB was impossible in the present study.
The false-negative rate with imprint cytology was 17.6%, and
in most cases, false negativity resulted from the presence of
micrometastases.
The ACOSOG Z1071 trial also reported that axillary
involvement became clinically undetectable in 83% of patients
evaluated after neoadjuvant chemotherapy and in 12% of
those with palpable nodules. In the women with breast cancer
with cN1 disease who received neoadjuvant chemotherapy
and who had two or more SLNs examined, the false-negative
rate exceeded 10%, which is considered acceptable. Given this
threshold of acceptability, changes in the management and
selection of patients to achieve greater sensitivity are needed
before SLNB can be accepted as an alternative to axillary
lymphadenectomy in this patient population (21).
Currently, intraoperative evaluations are performed
by imprint cytology, frozen section examination or both.
Although immunohistochemistry and intraoperative mole-
cular techniques are also available, they are not commonly
used (22).
Intraoperative imprint cytology is comparable to frozen
section examination for the rapid evaluation of the SLNB,
with the advantages of speed, reliability, reduced cost and
better tissue preservation (23,24). Furthermore, the surgeon
is alerted to the presence of a lymph node metastasis, thus
reducing the number of repeat axillary lymphadenectomy
surgeries, particularly in patients subjected to simple mas-
tectomy. This technique also allows patients and their
families to be informed immediately regarding lymph node
status (23).
The routine use of SLNB for the evaluation of residual
lymph node metastasis after neoadjuvant chemotherapy has
not been recommended for patients who initially tested
positive for malignancy. In these cases, axillary management
after neoadjuvant chemotherapy should be individualized
in accordance with the clinical subtype of the tumor, with
SLNB being performed in selected patients whenever pos-
sible (25).
Another study comparing imprint cytology with the
histological analysis of SLNs from patients with locally
advanced breast cancer subjected to neoadjuvant che-
motherapy concluded that imprint cytology could not be
recommended given the high rate of false negatives (12.01%)
observed in the study. Therefore, further studies are required
to validate the method (26).
In this study, the accuracy of imprint cytology, particularly
for the detection of macrometastases, was good. In addition,
specificity was excellent, namely, no negative lymph nodes
were identified as positive. Overall, the sensitivity of the
technique was poor for the detection of both macrometas-
tases and micrometastases. Although the method failed to
identify micrometastases, as reflected in the null sensitivity,
the sensitivity for the detection of macrometastases alone
was 83%. In this respect, there are indeed some limitations
with imprint cytology in the identification of micrometastases,
which can be detected by subsequent histology or immuno-
histochemistry (27).
With the objective of comparing imprint cytology to
histology for the evaluation of SLNs in 34 patients subjected to
neoadjuvant chemotherapy, Aguiar (28) reported a sensitivity
of 90.9%, with a false-negative rate of 7.46% and accuracy of
95.7%. Those results differ from the findings of the present
study in that the sensitivity in the present study was lower
(61.8%), and the false-negative rate in the present study was
17.6%. Nevertheless, the accuracy here was also good (86.3%).
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A study conducted by Dedivitis et al. (29) compared the
analysis of neck nodes by imprint cytology and FNA biopsy
in 86 patients and reported similar results, with a sensitivity
of 93.5%; a specificity of 100%; negative and positive predic-
tive values of 85.7% and 100%, respectively; and an accuracy
of 95.3%. Therefore, in view of the high accuracy associated
with imprint cytology, these authors suggested its use as an
additional aid to histology.
Intraoperative SLNB assessment by imprint cytology has
relied on the fact that patients may be spared a second
surgery when the SLN is positive (30). According to the
study by Tew K, et al., intraoperative imprint cytology has
a sensitivity of 63% with a false-negative rate of 37%, and
the pooled sensitivity for macrometastases is higher (81%)
than that for micrometastases (22%) (31). Our study showed
a false-negative rate of 17.6% for imprint cytology and a
sensitivity of 0% for micrometastases. In addition, since the
publication of the Z0011 trial (where patients with 1 or 2
positive SLNs did not benefit from a complete axillary
lymphadenectomy), the use of intraoperative assessment of
the SLN in the adjuvant setting has decreased (32). How-
ever, in the neoadjuvant chemotherapy setting, intraopera-
tive assessments of SLNs are still considered necessary. The
standard procedure for positive SLNs after neoadjuvant
chemotherapy is axillary lymphadenectomy, so patients with
positive SLNs intraoperatively may undergo axillary lym-
phadenectomy within the same surgery, avoiding the draw-
backs of a second surgery (33). For this reason, patients in
the neoadjuvant chemotherapy setting with intraoperative
false-negative imprint cytology results will require a second
surgery.
SLNB provides important information on lymph node
staging and reduces the morbidity associated with unneces-
sary axillary lymphadenectomy for patients with breast
cancer and no clinically detectable lymph node involvement.
The false-negative rate with imprint cytology, which is asso-
ciated with the number of lymph nodes removed, and the
complete response rate to neoadjuvant chemotherapy cur-
rently achieved are comparable to the rates published in the
literature. The accuracy of imprint cytology is good, and its
specificity is excellent for the detection of SLNs; however,
it fails to detect lymph node micrometastases, and this is
important because all patients with intraoperative imprint
cytology in the neoadjuvant chemotherapy setting who have
false-negative results, will require a second surgery.
Performing SLNB after neoadjuvant chemotherapy may
result in a high rate of false negatives, a finding that has
already been reported in several studies. Therefore, studies
such as this one, which are designed to compare methods
for the intraoperative analysis of SLNs with a definitive
histological diagnosis of a paraffin-embedded portion that
is analyzed by hematoxylin-eosin staining, are of utmost
importance.
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